Table 3.
Neurologic findings in patients with ATTRv Glu89Gln amyloidosis and predominantly neurologic or mixed phenotype
| Overall (n = 67) |
Bulgaria (n = 32) |
Italy (n = 28) |
Other countries (n = 7) |
|
|---|---|---|---|---|
| mPND score, n (%) | ||||
| 0 | 5 (7.5) | 3 (9.4) | 2 (7.1) | 0 (0.0) |
| I | 26 (38.8) | 13 (40.6) | 11 (39.3) | 2 (28.6) |
| II | 13 (19.4) | 8 (25.0) | 5 (17.9) | 0 (0.0) |
| IIIa | 2 (3.0) | 1 (3.1) | 1 (3.6) | 0 (0.0) |
| IIIb | 4 (6.0) | 1 (3.1) | 2 (7.1) | 1 (14.3) |
| IV | 2 (3.0) | 0 (0.0) | 1 (3.6) | 1 (14.3) |
| Missing | 15 (22.4) | 6 (18.8) | 6 (21.4) | 3 (42.9) |
ATTRv Glu89Gln amyloidosis ATTRv amyloidosis associated with the Glu89Gln variant, mPND modified peripheral neuropathy disability, THAOS Transthyretin Amyloidosis Outcomes Survey (data cutoff, January 6, 2020)